Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

whitePaper | October 4, 2022

Let’s just say what we’re all thinking: 2020 was rough. It threw every element of our lives into disarray. We suddenly had to become experts at navigating a new way of working, schooling and socialising. It was disruptive and it was challenging, but it was also transformative

whitePaper | November 24, 2022

Today’s pharmaceutical industry is facing big expectations and opportunities. Tasked with developing and manufacturing effective therapeutics and vaccines for an ongoing global pandemic,

whitePaper | October 14, 2022

COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessment.